Ministers are locked in a battle over the funding of price rises for NHS medicines under a trade deal with Donald Trump.

Keir Starmer’s government is in “advanced discussions” with Washington over a plan to increase the amount the NHS pays pharmaceutical firms for the drugs in return for avoiding tariffs imposed by Trump on the sector.

The proposals would see the limit at which a drug is deemed to be cost effective for the NHS raised, from its current range of between £20,000 to £30,000 for every additional year of good quality of life they provide, to as high as £50,000 per year of quality life. New Feature

In Short

Quick Stories. Same trusted journalism.

The move would mean the National Institute for Clinical Excellence (Nice), which approves the use of medicines in the NHS, gi

See Full Page